Abbvie Stock News

Marvell Technology, Inc. (MRVL) with the stream of -2.53% also noticed, India AbbVie Inc. (ABBV) encountered a rapid change of -1.81% in the last hour of Fridays trading session. Marvell The post Super Crazy Volume Spikes: Marvell Technology, Inc. (NASDAQ:MRVL), AbbVie Inc. (NYSE:ABBV) appeared first on Stocks Equity .

WESPAC Advisors LLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 133.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,437 shares of the companys stock after purchasing an additional 8,256 shares during the quarter. WESPAC Advisors LLCs holdings in []

Capital Asset Advisory Services LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 1.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,730 shares of the companys stock after purchasing an additional 242 shares during the period. Capital Asset []

Capital Asset Advisory Services LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 1.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,730 shares of the companys stock after buying an additional 242 shares during the quarter. Capital Asset Advisory Services []

Wedge Capital Management L L P NC decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 271,217 shares of the company’s stock after selling 12,955 shares during the quarter. Wedge Capital Management L L […]

Hollencrest Capital Management grew its stake in AbbVie Inc. (NYSE:ABBV) by 11.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,009 shares of the companys stock after acquiring an additional 800 shares during the quarter. Hollencrest Capital Managements holdings in AbbVie were worth []

Drivers During the forecast period, the global methicillin-resistant staphylococcus aureus (MRSA) drugs market is projected to rise due to an increase in the number of pipeline products for MRSA medicines. Destiny Pharma obtained an experimental new medication application from the FDA

Societe Generale upgraded shares of AbbVie (NYSE:ABBV) from a hold rating to a buy rating in a research note issued to investors on Tuesday, Price Targets.com reports. A number of other brokerages have also weighed in on ABBV. Morgan Stanley boosted their target price on AbbVie from $116.00 to $124.00 and gave the stock an []

AbbVie (NYSE:ABBV) had its price objective boosted by stock analysts at Truist from $118.00 to $135.00 in a research note issued on Wednesday, The Fly reports. The brokerage currently has a buy rating on the stock. Truists price objective would suggest a potential upside of 13.77% from the stocks previous close. ABBV has been the []

Appleton Partners Inc. MA raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,555 shares of the companys stock after acquiring an additional 2,909 shares during the period. Appleton Partners []

Pacific Wealth Strategies Group Inc. lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,402 shares of the companys stock after acquiring an additional 147 shares during the quarter. []

WESPAC Advisors SoCal LLC decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 26.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,626 shares of the company’s stock after selling 22,941 shares during the quarter. AbbVie makes up 2.3% […]

Investors Asset Management of Georgia Inc. GA ADV boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 11.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 19,571 shares of the companys stock after purchasing an additional 1,945 shares during the quarter. AbbVie makes up 1.1% of Investors Asset Management of Georgia Inc. GA ADVs []

DUBLIN--(BUSINESS WIRE)--The "Cellulitis - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com''s offering. This clinical trial report provides an overview of the Cellulitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cellulitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials

AbbVie (NYSE:ABBV) had its price target boosted by Truist from $118.00 to $135.00 in a research note released on Wednesday, The Fly reports. Truist currently has a buy rating on the stock. A number of other research analysts also recently weighed in on the stock. Barclays increased their target price on shares of AbbVie from []